<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Only few studies have addressed the pathogenesis and treatment of the non-criteria manifestations of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) such as <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, <z:e sem="disease" ids="C0018824" disease_type="Disease or Syndrome" abbrv="">cardiac valve disease</z:e>, <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e>, <z:hpo ids='HP_0200042'>skin ulcers</z:hpo>, or diffuse <z:mp ids='MP_0001182'>pulmonary hemorrhage</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>There is no consensus on the management of these manifestations; they may occur despite full-dose anticoagulation or may not improve if anticoagulation is initiated after their discovery </plain></SENT>
<SENT sid="2" pm="."><plain>This brief review may help physicians in the management of the non-criteria manifestations of aPL </plain></SENT>
</text></document>